Ardelyx Inc. (ARDX) Boosts Global Presence via Kyowa Kirin Partnership

Ardelyx, Inc. (ARDX) reported record prescription volumes and net sales growth in Q2 2025, with revenues reaching $97.7 million. The company strengthened its leadership team and pursues international expansion through partnerships, such as with Kyowa Kirin, to broaden tenapanor's global reach. IBSRELA sales increased 57% YoY, and XPHOZAH also showed strong growth.

Ardelyx, Inc. (ARDX) reported robust financial performance in the second quarter of 2025, with revenues reaching $97.7 million, a 33% year-over-year growth. The company's key products, IBSRELA and XPHOZAH, demonstrated significant sales growth, driving Ardelyx's overall success [1].

IBSRELA, a treatment for irritable bowel syndrome with constipation (IBS-C), saw a substantial 84% year-over-year increase in net sales, reaching $65 million. This growth was attributed to increased field activities, effective marketing programs, and expanded reach. Ardelyx raised its full-year 2025 net sales revenue guidance for IBSRELA to $250 million - $260 million, with peak sales expectations exceeding $1 billion [1].

XPHOZAH, a chronic kidney disease (CKD) treatment, showed a 7% increase in net sales compared to Q1 2025, reaching $25 million. The company is navigating the new market landscape for phosphate management, with peak sales expectations remaining at $750 million [1].

Ardelyx also strengthened its leadership team, appointing experienced executives to key roles, including Mike Kelliher as Chief Business Officer and Laura Williams as Chief Patient Officer. The company continues to pursue international expansion, with partnerships like those with Kyowa Kirin to broaden the reach of tenapanor [1].

Despite strong performance, Ardelyx acknowledged certain challenges, including typical summer seasonality impacting prescription trends and the ongoing CMS legal proceedings. The company remains confident in its ability to navigate these dynamics and achieve its financial goals [1].

References:

[1] https://www.datainsightsmarket.com/companies/ARDX